Literature DB >> 33777797

Circulating Genetically Abnormal Cells Add Non-Invasive Diagnosis Value to Discriminate Lung Cancer in Patients With Pulmonary Nodules ≤10 mm.

Maosong Ye1, Xiaoxuan Zheng2,3, Xin Ye4,5,6, Juncheng Zhang4,5, Chuoji Huang4,5, Zilong Liu1, Meng Huang4,5, Xianjun Fan4,5, Yanci Chen4,5, Botao Xiao6, Jiayuan Sun2,3, Chunxue Bai1.   

Abstract

BACKGROUND: Lung cancer screening using low-dose computed tomography (LDCT) often leads to unnecessary biopsy because of the low specificity among patients with pulmonary nodules ≤10 mm. Circulating genetically abnormal cells (CACs) can be used to discriminate lung cancer from benign lung disease. To examine the diagnostic value of CACs in detecting lung cancer for patients with malignant pulmonary nodules ≤10 mm.
METHODS: In this prospective study, patients with pulmonary nodules ≤10 mm who were detected at four hospitals in China from January 2019 to January 2020 were included. CACs were detected using fluorescence in-situ hybridization. All patients were confirmed as lung cancer or benign disease by further histopathological examination. Multivariable logistic regression models were established to detect the presence of lung cancer using CACs and other associated characteristics. Receiver operating characteristic analysis was used to evaluate the performance of CACs for lung cancer diagnosis.
RESULTS: Overall, 125 patients were included and analyzed. When the cutoff value of CACs was >2, the sensitivity and specificity for lung cancer were 70.5 and 86.4%. Male (OR = 0.330, P = 0.005), maximum solid nodule (OR = 2.362, P = 0.089), maximum nodule located in upper lobe (OR = 3.867, P = 0.001), and CACs >2 (OR = 18.525, P < 0.001) met the P < 0.10 criterion for inclusion in the multivariable models. The multivariable logistic regression model that included the dichotomized CACs (>2 vs. ≤2) and other clinical factors (AUC = 0.907, 95% CI = 0.842-0.951) was superior to the models that only considered dichotomized CACs or other clinical factors and similar to the model with numerical CACs and other clinical factors (AUC = 0.913, 95% CI = 0.850-0.956).
CONCLUSION: CACs presented a significant diagnostic value in detecting lung cancer for patients with pulmonary nodules ≤10 mm.
Copyright © 2021 Ye, Zheng, Ye, Zhang, Huang, Liu, Huang, Fan, Chen, Xiao, Sun and Bai.

Entities:  

Keywords:  circulating genetically abnormal cell (CAC); early detection; early diagnosis; lung cancer; pulmonary nodule

Year:  2021        PMID: 33777797      PMCID: PMC7991838          DOI: 10.3389/fonc.2021.638223

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  26 in total

1.  Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Authors:  N Haruki; T Harano; A Masuda; T Kiyono; T Takahashi; Y Tatematsu; S Shimizu; T Mitsudomi; H Konishi; H Osada; Y Fujii; T Takahashi
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Diagnostic performance of percutaneous core-needle lung biopsy under CT scan fluoroscopic guidance for pulmonary lesions measuring ≤10 mm.

Authors:  Yoshikane Yamauchi; Yotaro Izumi; Seishi Nakatsuka; Masanori Inoue; Yuichiro Hayashi; Mitsutomo Kohno; Takashi Ohtsuka; Masaki Anraku; Taichiro Goto; Hiroaki Nomori
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

Review 3.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2016-04-21       Impact factor: 15.609

4.  Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios.

Authors:  Juliana Bueno; Luis Landeras; Jonathan H Chung
Journal:  Radiographics       Date:  2018 Sep-Oct       Impact factor: 5.333

5.  Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients.

Authors:  T Schenk; J Ackermann; C Brunner; P Schenk; N Zojer; S Roka; J Drach
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

6.  Survival of patients with stage I lung cancer detected on CT screening.

Authors:  Claudia I Henschke; David F Yankelevitz; Daniel M Libby; Mark W Pasmantier; James P Smith; Olli S Miettinen
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

Review 7.  Using Clinical Risk Models for Lung Nodule Classification.

Authors:  Stephen A Deppen; Eric L Grogan
Journal:  Semin Thorac Cardiovasc Surg       Date:  2015-04-07

8.  A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules.

Authors:  Michael K Gould; Lakshmi Ananth; Paul G Barnett
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

9.  Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

Authors:  Anieta M Sieuwerts; Jaco Kraan; Joan Bolt; Petra van der Spoel; Fons Elstrodt; Mieke Schutte; John W M Martens; Jan-Willem Gratama; Stefan Sleijfer; John A Foekens
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

10.  Evaluation of a Serum Lung Cancer Biomarker Panel.

Authors:  Peter J Mazzone; Xiao-Feng Wang; Xiaozhen Han; Humberto Choi; Meredith Seeley; Richard Scherer; Victoria Doseeva
Journal:  Biomark Insights       Date:  2018-01-15
View more
  2 in total

1.  Editorial: Surgical Selection of Sublobar Resection and Scope of Lymph Node Dissection for Early-Stage Lung Cancer.

Authors:  Jiajing Sun; Chengchu Zhu; Jianfei Shen
Journal:  Front Surg       Date:  2022-05-11

2.  Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.

Authors:  Han Yang; Hongjie Chen; Guorui Zhang; Hongyi Li; Ran Ni; Yali Yu; Yepeng Zhang; Yongjun Wu; Hong Liu
Journal:  BMC Cancer       Date:  2022-04-09       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.